Amgen buys cancer drugmaker for $10.4B

08/26/2013 | Reuters

Amgen agreed to acquire Onyx Pharmaceuticals for $125 per share, or around $10.4 billion, in the fifth-largest biotechnology deal ever. The agreement will give Amgen rights to several cancer drugs, including the multiple myeloma drug Kyprolis, liver and kidney cancer treatment Nexavar, and colon cancer drug Stivarga. The acquisition is expected to be finalized this year.

View Full Article in:

Reuters

Published in Briefs:

SmartBrief Job Listings for Health Care

Job Title Company Location
Senior Director, Biostatistics
Edwards Lifesciences
Irvine, CA
Diagnostic Technician
Roche
Marlborough, MA
Test Technician
Roche
Marlborough, MA
Associate - Food and Drug
Keller and Heckman LLP
Washington, DC
Senior Paralegal - Research & Development, and Medical
Boehringer Ingelheim
Ridgefield, CT